Stephens Investment Management Group LLC Decreases Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Stephens Investment Management Group LLC cut its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,351,331 shares of the specialty pharmaceutical company’s stock after selling 55,191 shares during the quarter. Stephens Investment Management Group LLC’s holdings in Supernus Pharmaceuticals were worth $69,850,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Sit Investment Associates Inc. grew its stake in shares of Supernus Pharmaceuticals by 0.4% during the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock worth $3,240,000 after acquiring an additional 250 shares during the period. Maryland State Retirement & Pension System raised its stake in Supernus Pharmaceuticals by 3.6% in the 4th quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after acquiring an additional 290 shares during the period. SummitTX Capital L.P. lifted its holdings in Supernus Pharmaceuticals by 2.7% during the fourth quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock valued at $580,000 after purchasing an additional 303 shares during the last quarter. Royal Bank of Canada lifted its holdings in Supernus Pharmaceuticals by 5.4% during the fourth quarter. Royal Bank of Canada now owns 6,987 shares of the specialty pharmaceutical company’s stock valued at $346,000 after purchasing an additional 355 shares during the last quarter. Finally, Covestor Ltd boosted its position in Supernus Pharmaceuticals by 16.2% during the fourth quarter. Covestor Ltd now owns 2,683 shares of the specialty pharmaceutical company’s stock worth $133,000 after purchasing an additional 374 shares during the period.

Analyst Upgrades and Downgrades

SUPN has been the subject of several recent research reports. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Supernus Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $62.17.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $48.05 on Friday. Supernus Pharmaceuticals, Inc. has a 52 week low of $31.35 and a 52 week high of $59.68. The business has a 50-day simple moving average of $47.18 and a two-hundred day simple moving average of $49.50. The company has a market cap of $2.79 billion, a P/E ratio of -94.22, a P/E/G ratio of 1.03 and a beta of 0.54.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.